Proteomic Analysis Reveals Molecular Differences in the Development of Gastric Cancer

Rinchen Dhondrup,1 XiaoKang Zhang,2 Xuemei Feng,3 Dhondrup Lobsang,1 Qincuo Hua,1 Junli Liu,4 Ying Cuo,3 Sangji Zhuoma,3 Geri Duojie,1 Suonan Duojie Caidan,1 and Samdrup Gyal1

1Tibetan Medical College of Qinghai University, Xining 810016, Qinghai, China
2Jingjie PTM Bio (Hangzhou) Co.Ltd, Hangzhou 310018, Zhejiang, China
3Qinghai Provincial Tibetan Hospital, Xining 810007, Qinghai, China
4Affiliated Hospital of Qinghai University, Xining 810000, Qinghai, China

Correspondence should be addressed to Rinchen Dhondrup; 2731435914@qq.com

Received 15 February 2022; Revised 18 June 2022; Accepted 23 June 2022; Published 31 July 2022

Academic Editor: Talha Bin Emran

Copyright © 2022 Rinchen Dhondrup et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gastric cancer (GC) is the 3rd leading cause of death from cancer and the 5th most common cancer worldwide. The detection rate of GC among Tibetans is significantly higher than that in Han Chinese, probably due to differences in their living habits, dietary structure, and environment. Despite such a high disease burden, the epidemiology of gastric cancer has not been studied in this population. Molecular markers are required to aid the diagnosis and treatment of GC. In this study, we collected gastric tissue samples from patients in Tibet with chronic nonatrophic gastritis (CNAG) (n = 6), chronic atrophic gastritis (CAG) (n = 7), gastric intraepithelial neoplasia (GIN) (n = 4), and GC (n = 5). The proteins in each group were analyzed using coupled label-free mass spectrometry. In addition, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, and protein interaction networks were used to analyze the differentially expressed proteins (DEPs) among groups. DEPs were quantified in comparisons of GC versus CNAG (223), GC versus GIN (100), and GIN versus CNAG (341). GO and KEGG analyses showed that the DEPs were mainly associated with immunity (GC versus CNAG) and cancer proliferation and metastasis (GC versus GIN, and GIN versus CNAG). Furthermore, the expression levels of cell proliferation and cytoskeleton-related proteins increased consistently during cancer development, such as ITGA4, DDC, and CPT1A; thus, they are potential diagnostic markers. These results obtained by proteomics analysis could improve our understanding of cancer biology in GC and provide a rich resource for data mining and discovering potential immunotherapy targets.

1. Introduction

GC is the fifth most common cancer and the third leading cause of cancer mortality globally, and it is a highly heterogeneous disease at the genetic and molecular levels [1, 2]. The number of GC cases in Asia accounts for more than half of the global cases, especially those in East Asia. The factors associated with GC include a high-salt diet, low intake of fruits and vegetables, smoking, and a family history of GC [3]. In addition, etiological factors, including a variety of genetic and epigenetic changes, are related to the GC process [4]. GC mainly develops through atrophic gastritis and intestinal metaplasia in a precancerous state. Cancer develops via a series of mucosal changes from nonatrophic gastritis to atrophic gastritis, intestinal metaplasia (IM), and GIN to GC [5, 6]. The prognosis of advanced GC is still very poor, but an early prognosis of GC can ensure long-term survival [7]. Precancerous lesions of gastric carcinoma comprise a class of GC that is closely related to changes in gastric mucosal pathology, with a key role in the progression of normal gastric mucosal cells into gastric cancerous cells [8]. It is not clear whether some or all of these lesions are
directly involved in the development of GC. Early effective intervention is important for preventing and controlling GC [9]. Therefore, determining the relationship between pre-malignant lesions and the development of GC has important clinical significance for the early detection and treatment of GC.

Reliable biomarkers and potential therapeutic targets are highly desirable for understanding and treating GC, and they have been investigated widely [10]. High-throughput omics techniques can be used to study the development of GC and the associated molecular mechanisms with unprecedented speed and in great detail [11]. Many previous studies of GC focused on the genome and transcriptome levels. GC-driven genes and abnormal regulatory pathways have been determined at the genome and transcription levels, thereby greatly improving our understanding of GC [12]. Genomic changes should be translated into changes at the protein level to affect the phenotype [13]. Proteomics can be used to study the characteristics of cells, tissues, or biologica...
fractions using a stepwise increasing acetonitrile concentration gradient (6%, 9%, 12%, 15%, 18%, 21%, 25%, 30%, and 35%) under basic conditions (pH 10), before analyzing with liquid chromatography–MS/MS (LC-MS/MS). General workflow for functional proteomics analyses in CNAG, CAG, GIN, and GC (Figure 1(a)).

2.3. LC-MS/MS Analysis. LC-MS/MS analysis was performed as previously described [32,33]. Peptide samples were fractionated by high-pressure liquid chromatography (HPLC; Thermo EASY-nLC System, Waltham, MA, USA), where mobile phase A comprised 0.1% (v/v) formic acid in Milli-Q water and B comprised 0.1% formic acid in 100% acetonitrile. Peptides were eluted by HPLC with a mobile phase gradient of 5–35% at a flow rate of 600 nL/min for 75 min. The samples were then analyzed with Orbitrap Fusion, Orbitrap Fusion Lumos, and Q Exactive Plus mass spectrometers (Thermo Fisher Scientific, Rockford, IL, USA) coupled to an EASY-nLC 1000 nanoflow LC system (Thermo Fisher Scientific, Rockford, IL USA). MS/MS analysis was performed in the data-dependent mode. One full scan (300–1400 m/z, R = 60,000 at 200 m/z) was followed by up to 20 data-dependent MS/MS scans with higher-energy collision dissociation (target 2 × 10^5 ions, maximum injection time 40 ms, isolation window 1.6 m/z, normalized collision energy of 27%).

2.4. Peptide Identification and Protein Quantification. The raw MS files were processed as described in a previous study [34]. Briefly, raw files were searched against the human National Center for Biotechnology Information (NCBI) RefSeq protein database (Homo_sapiens_9606_SP_20201214 fasta, 20395 sequences) using Mascot 2.3 (Matrix Science Inc., Boston, MA, USA, version 2.2.1). The mass tolerance was set to 20 ppm for precursor ions, 50 ppm for product ions collected by QExactive HF, and 0.5 Da for product ions collected by Fusion. KR is a proteolytic cleavage site and it allows up to two missed cleavages. The database search engine set cystine carbamoyl methylation as a fixed modification and N-acetylation and methionine oxidation as variable modifications. In all of the identified peptides, peptide ions with a charge state of +1 or >4 and a different ratio for proteins of <2.0-fold or >0.5-fold were excluded, and the false discovery rate was adjusted to 1%. Intensity-based absolute quantification (iBAQ) was applied for protein quantification, and the iBAQ values were converted into iFOT values (fraction of total, iBAQ value of each protein divided by the sum of all iBAQ values of all proteins in the sample) as described previously [35]. The iFOT values were used to quantify low-abundance proteins. The false discovery rate for proteins was equal to the ratio of the number of assembled proteins from decoy database searches relative to the number of assembled proteins from target database searches.

2.5. MS Platform Quality Control (QC). The trypsin in the tissue lysates was tested as a QC standard for MS. The QC standard was produced and operated using the same methods and conditions with the same software and GC parameters. We evaluated quantitative protein repeatability using three statistical analysis methods: Pearson’s correlation coefficient, principal component analysis (PCA), and relative standard deviation.

2.6. Bioinformatics and Statistical Analysis. Limited selections were used to screen label-free quantitative data before DEPs analysis, as follows: (1) proteins with the same peptide found in two to three samples were included; (2) the protein identification confidence was set to 95%, and the false positive rate was less than 5% in the database; (3) the difference ratio of proteins was more than the 2.0-fold and the p-value was less than 0.05. Th DEPs were analyzed based on the GO secondary annotations. DEPs were classified using the GO database according to molecular function, cellular component, and biological process categories, and the significance of each protein function classification was determined using Fisher’s exact test. To identify representative proteins in each tissue sample and determine their biological significance, we also conducted comparisons using the KEGG database (http://www.genome.jp/kegg/) to identify possibly enriched pathways. In addition, protein interaction network analysis and analyses of the similarities and differences in the DEPs between groups were conducted to identify the functional properties of the DEPs and their relevance to the research goal. For each category, a two-tailed Fisher’s exact test was employed to test the enrichment of the DEPs against all identified proteins. The GO with a corrected p-value < 0.05 was considered significant. KEGG database was used to identify enriched pathways by a two-tailed Fisher’s exact test to test the enrichment of the DEPs against all identified proteins. The pathway with a corrected p-value < 0.05 was considered significant. These pathways were classified into hierarchical categories according to the KEGG website. For further hierarchical clustering based on differentially expressed protein functional classification, we first collated all the categories obtained after enrichment along with their p values and then filtered for those categories which were at least enriched in one of the clusters with p value < 0.05. This filtered p value matrix was transformed by the function $x = -\log_{10}(p)$ value. Finally these x values were z-transformed for each functional category. These z scores were then clustered by one-way hierarchical
clustering (Euclidean distance, average linkage clustering) in Genesis. After comparing the DEPs in different groups with the STRING (v.11.0) protein network interaction database, the interactions between the DEPs were obtained based on a confidence score >0.7 (high confidence). The protein-protein interactions (PPI) of dysregulated proteins predicted by STRING showed that most could interact with each other. STRING analysis showed that the DEPs formed strong networks with dynamic clusters.

Figure 1: (a) General workflow of MS-based quantitative proteomics and bioinformatics analyses. (b) Two-dimensional scatter plot obtained by principal component analysis showing the distribution of all the quantified protein samples. (c) Detection of the precision of proteins extracted from tissues.
3. Results

3.1. Protein Identification in Gastric Tissue Samples. We identified 100, 223, and 341 dysregulated proteins using Proteome Discoverer 1.4 in the comparisons of GC versus GIN, GC versus CNAG, and GIN versus CNAG, respectively (Figure 2). PCA and the Pearson’s correlation coefficient indicated good quantitative repeatability (Figures 1(b) and

![Figure 2](image-url)
Figure 3: Continued.
We determined the expression levels of 100 proteins in GC versus GIN, where 41 proteins were upregulated, and 59 proteins were downregulated. The expression levels of 223 proteins were determined in GC versus CNAG, where 85 proteins were upregulated, and 138 proteins were downregulated. The expression levels of 341 proteins were determined in GIN versus CNAG, where 205 proteins were upregulated, and 136 proteins were downregulated (Figure 2 and Supplementary Material 2).

3.2. Subcellular Structural Localizations of DEPs. The development of GC is strictly regulated by a series of signaling events and effectors. We conducted analyses to further investigate the functions of the DEPs. The subcellular localization indicated that the DEPs were annotated as cytoplasmic for GC versus GIN (Figure 3(a)). For GC versus CNAG, the results showed that the upregulated proteins were located in the cytoplasm and nucleus, and the downregulated proteins were located in the cytoplasm and extracellular areas (Figure 3(b)). For GIN versus CNAG, the upregulated proteins were annotated as located in the cytoplasm and nucleus, and the downregulated proteins were located in the cytoplasm, extracellular areas, and nucleus (Figure 3(c)). The cytoplasm is the main site for biochemical reactions. These results indicate that proteins in the cytoplasm and nucleus may play important roles in the development of GC.

3.3. Functional Annotations of DEPs Using GO. Furthermore, the DEPs quantified in each group were statistically analyzed based on GO primary annotations. The DEPs were classified into three categories (biological process, cellular component, and molecular function) based on GO annotations to assess the biological roles of the proteins from different perspectives. The GO enrichment analysis results for the DEPs were similar for GC versus GIN (Figure 4(a)), GC versus CNAG (Figure 4(b)), and GIN versus CNAG (Figure 4(c)), where they were mostly associated with a cellular process and biological regulation, and the molecular functions of these proteins were mainly related to catalytic activity and binding (Figure 5).

3.4. GO Enrichment Analysis. For GC versus GIN, DEPs were mainly involved in the regulation of blood circulation and epithelial cell development in the biological process category, related to the Golgi apparatus in the cellular component category, and mainly related to T cell receptor binding and transferase activity in the molecular function category. For GC versus CNAG, DEPs were mainly involved in actin-myosin filament sliding and glycoprotein metabolic process in the biological process category, related to immunoglobulin complex, circulating and endoplasmic reticulum chaperone complex in the cellular component category, and mainly related to immunity and protein synthesis in the molecular function category. For GIN versus CNAG, the DEPs were related to substrate adhesion-dependent cell spreading and regulation of leukocyte proliferation in the biological process category, related to the phagocytic cup in the cellular component category, and mainly related to MHC class II receptor activity and cell-cell adhesion mediator activity in the molecular function category (Figure 6).

3.5. KEGG Pathway Enrichment Analysis. KEGG enrichment analysis for GC versus GIN showed that the proteins were mainly involved in fatty acid metabolism and...
Figure 4: Continued.
biosynthesis. For GC versus CNAG, the DEPs were enriched in aminoacyl-tRNA biosynthesis and insulin resistance. For GIN versus CNAG, the DEPs were enriched in intestinal immunity and inflammation, tryptophan metabolism, regulation of actin cytoskeleton, and extracellular matrix-receptor interaction (Figure 7).

### 3.6. Protein-Protein Interaction Network Analysis

The cluster for GC versus GIN was mostly related to energy metabolism, cancer metastasis, and invasions, such as LAMTOR1 and TOM1 (Figure 8(a)). The cluster identified for GC versus CNAG contained proteins related to cell proliferation and migration, such as HSPD1, TOMM40, TIMM13, and TIMM8A, GTF2F2, RRP12, WDRL75, GLMN, and WDR43 (Figure 8(b)). The cluster for GIN versus CNAG was mainly related to cell proliferation, cell migration, and invasions, such as PYGB, FABP5, ITGA4, ITGA9, RBX11, ARF6, PAK4, GIT1, and COMMD8 (Figure 8(c)).

### 3.7. Enrichment Clustering Analysis

As shown in the clustered heatmap in Figure 9, the expression levels of proteins associated with cancer migration and gastric carcinogenesis were elevated during cancer development, where the signaling pathways for these proteins included gastric carcinogenesis and cancer migration. By contrast, the expression levels of immune and cytosolic factor-related proteins were decreased during cancer development, and these proteins were enriched in cellular pathways related to the complement system and immune system. According to our analysis, the expression levels of neutrophil-mediated, leukocyte-mediated, and immune-associated proteins were decreased from CNAG to CAG, whereas the expression levels of these proteins increased gradually during cancer progression. These immune-related proteins were mainly associated with transcriptional misregulation in cancer and the IL-17 signaling pathway. The expression levels of proteins related to lipid metabolism were higher in the GIN versus CNAG group than in the GC versus CNAG group, and these proteins were strongly associated with the Jak-STAT signaling pathway and steroid hormone biosynthesis. The expression levels of cancer migration-associated proteins were lowest in GIN, whereas the expression levels of these proteins were elevated during the progression from GIN to GC. These proteins activated pathways associated with complement and coagulation cascades and cancer migration.

### 4. Discussion

GC is one of the most common cancers throughout the world, and it has a high mortality rate (5). Early diagnostic screening and providing effective drug intervention targets are reliable methods for the detection and treatment of GC. However, the related molecules and regulatory mechanisms for GC are unclear, especially the key signaling pathways and
Figure 5: Clustered heatmap analysis of the differential proteins in CNAG, CAG, GIN, GC groups. Each column represents the protein information of one group of samples, and each row represents the relative expression level of each protein.

Figure 6: Biological process, cellular component, and molecular function analyses of the DEPs using the GO database.

optimum early markers and targets. In this study, we used proteomics to investigate gastric tissue samples collected from GC, GIN, CAG, and CNAG patients and identified DEPs related to GC to detect potentially important molecular and signaling networks, carcinogenic mechanisms, and specific biomarkers for GC diagnosis and treatment. CNAG is the most common type of chronic gastritis, and the risk of CAG is increased for patients with CNAG [36]. In this study, we identified and quantified a higher number of dysregulated proteins for GC versus CNAG. Further analysis showed that all of these dysregulated proteins had cancer-related associations, such as PDIA5 [37], DEF6 [38], MZB1...
null
Figure 8: Continued.
(b)

Figure 8: Continued.
gastric carcinogenesis increased consistently during cancer formation and progression, such as ITGA4, DDC, and CPT1A. ITGA4 is an adhesion molecule that is actively involved in cellular extravasation [55]. Lymphovascular invasion (LVI) and nerve invasion (PNI) are two important pathological parameters, and ITGA4 is a reliable marker for the simultaneous detection and diagnosis of LVI and PNI, where it has been detected in colon, prostate, esophageal, lung, kidney, uterine, tongue, bladder, and liver cancers [56]. DDC is an enzyme involved in the biosynthetic pathway for the neurotransmitters dopamine and serotonin. DDC can be used to detect peritoneal micrometastases of GC with good sensitivity and specificity, especially for poorly differentiated adenocarcinomas [57]. The enzyme CPT1A resides in the outer mitochondrial membrane, and it catalyzes the reversible transfer of acyl groups between coenzyme A (CoA) and L-carnitine to convert acyl-CoA esters into acyl-carnitine esters [58]. CPT1A-mediated fatty acid oxidation promotes the metastasis of colorectal cancer cells by inhibiting anoikis [59]. Our findings also suggested that the expression levels of immune-related proteins were decreased, such as GMPR and HLA-DPB1. Lower expression of the HLA-DPB1 gene may lead to increased aggressive disease in adult adrenocortical tumors [60]. GMPR is closely associated with the formation of an invasive footprint, in vitro invasion, and the growth of melanoma cells [61]. The results obtained in previous studies combined with our findings indicate that the growth and invasion of cancer cells are important
processes in GC formation and progression. Iuga et al. [32] suggested that upregulated proteins are more suitable as potential biomarkers than downregulated proteins during the development of GC. Therefore, we consider that the combination of ITGA4, DDC, and CPT1A could be used as potential diagnostic markers for GC. However, the value and utility of these protein molecules as potential biomarkers are still debatable and need to be fully validated.

In this study, we found that immunity, cell proliferation, and metastasis-related proteins may play important roles in the occurrence and progression of GC, and they are potential diagnostic markers for GC. Further studies are needed to verify whether these DEPs can be used as diagnostic markers for GC and whether they are targets for GC treatment.

Figure 9: Proteins clustered and analyzed in GC, GIN, CNAG, and CAG according to biological processes with the GO and KEGG databases. Five clusters were determined by coexpression analysis. Left: coexpression patterns of the proteins in the five clusters. Right: representative GO terms for each cluster.

Figure 10: Venn diagrams showing the differences and similarities of differentially expressed proteins determined in the comparison of GC versus CNAG in our study, and nearby tissue-specific, and tumor-differentiated proteins analyzed by Ge et al.
5. Conclusion

Our findings provide a valuable resource for the early diagnosis and treatment of GC. Immunity, cell proliferation, and metastasis-related proteins related proteins are associated with the development and progression of GC. The DEPs were mainly associated with immunity (GC versus CNAG) and cancer proliferation and metastasis (GC versus GIN and GIN versus CNAG). ITGA4, DDC, and CPTIA are potentially diagnostic markers for GC.

Data Availability

The data used to support the findings of the study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by the https://doi.org/10.13039/501100011501 Qinghai Provincial Science and Technology Project-Applied Basic Research Program (Grant no. 2018-ZJ-732) and the https://doi.org/10.13039/501100012166 National Key R&D Program of China (Grant no. 2017YFC1703902).

Supplementary Materials

Additional file 1: Clinical characteristics and pathology of patients in this study. (Supplementary Materials (1)) Additional file 2: All upregulated (ratio ≥1.4) and downregulated proteins (ratio ≤0.714) in the comparisons of GC versus GIN, GC versus CNAG, and GIN versus CNAG are presented. (Supplementary Materials (2)). (Supplementary Materials)

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.
[2] E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken, and F. Lordick, “Gastric cancer,” The Lancet, vol. 396, no. 10251, pp. 635–648, 2020.
[3] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[4] J. E. Talmadge and I. J. Fidler, “AACR centennial series: the biology of cancer metastasis: historical perspective,” Cancer Research, vol. 70, no. 14, pp. 5649–5669, 2010.
[5] J. G. Kusters, A. H. M. van Vliet, and E. J. Kuipers, “Pathogenesis of Helicobacter pylori infection,” Clinical Microbiology Reviews, vol. 19, no. 3, pp. 449–490, 2006.
[6] Y. Zhang, X. Wu, C. Zhang et al., “Dissecting expression profiles of gastric precancerous lesions and early gastric cancer to explore crucial molecules in intestinal-type gastric cancer tumorigenesis,” The Journal of Pathology, vol. 251, no. 2, pp. 135–146, 2020.
[7] P. Hohenberger and S. Gretschen, “Gastrectomy,” The Lancet, vol. 362, no. 9380, pp. 305–315, 2003.
[8] X. Zhang, C. Li, W. Cao, and Z. Zhang, “Alterations of gastric microbiota in gastric cancer and precancerous stages,” Frontiers in Cellular and Infection Microbiology, vol. 11, Article ID 559148, 2021.
[9] S. Ge, X. Xia, C. Ding et al., “A proteomic landscape of diffuse-type gastric cancer,” Nature Communications, vol. 9, p. 1012, 2018.
[10] S. Mereiter, M. Balmáña, J. Gomes, A. Magalhães, and C. A. Reis, “Glycomic approaches for the discovery of targets in gastrointestinal cancer,” Front Oncol, vol. 6, p. 55, 2016.
[11] M. Abyadeh, A. Meyfours, V. Gupta et al., “Recent advances of functional proteomics in gastrointestinal cancers—a path towards the identification of candidate diagnostic, prognostic, and therapeutic molecular biomarkers,” International Journal of Molecular Sciences, vol. 21, no. 22, p. 8532, 2020.
[12] T. Takahashi, A. Elzawhary, S. Mimaki et al., “Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors,” Genes Chromosomes & Cancer, vol. 56, no. 4, pp. 303–313, 2017.
[13] D. G. Mun, J. Bhin, S. Kim et al., “Proteogenomic characterization of human early-onset gastric cancer,” Cancer Cell, vol. 35, no. 1, p. 111, 2019.
[14] F. Li, B. Yang, Y. Liu et al., “Acupuncture regulates serum differentially expressed proteins in patients with chronic atrophic gastritis: a quantitative iTRAQ proteomics study,” Evidence-based Complementary and Alternative Medicine, vol. 2021, pp. 1–19, 2021.
[15] Y. W. Kwon, H. S. Jo, S. Bae et al., “Application of proteomics in cancer: recent trends and approaches for biomarkers discovery,” Frontiers of Medicine, vol. 8, Article ID 747333, 2021.
[16] C. Planque, V. Kulasingam, C. R. Smith, K. Reckamp, L. Goodglick, and E. P. Diamandis, “Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines,” Molecular & Cellular Proteomics, vol. 8, no. 12, pp. 2746–2758, 2009.
[17] X. Li, C. Zhang, T. Gong et al., “A time-resolved multi-omic atlas of the developing mouse stomach,” Nature Communications, vol. 9, p. 4910, 2018.
[18] F. J. Veloso, A. R. Campos, M. C. Sogayar, and R. G. Correa, “Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation,” BMC Genomics, vol. 20, p. 152, 2019.
[19] X. T. Zhou, J. Ding, H. Y. Li et al., “Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma,” Journal of Cellular and Molecular Medicine, vol. 24, no. 7, pp. 4298–4311, 2020.
[20] Y. Zeng, M. Ren, Y. Li et al., “Knockdown of RhoGDI2 mediates drug resistance through targeting TAP1 in hepatocellular carcinoma,” Cancer Letters, vol. 492, pp. 136–146, 2020.
[21] B. Zhang, J. Wang, X. Wang et al., “Proteogenomic characterization of human colon and rectal cancer,” Nature, vol. 513, no. 7518, pp. 382–387, 2014.
[22] P. Mertins, D. R. Mani, K. V. Ruggles et al., “Proteogenomics connects somatic mutations to signalling in breast cancer,” Nature, vol. 534, no. 7605, pp. 55–62, 2016.
[23] H. Zhang, T. Liu, Z. Zhang et al., “Integrated proteogenomic characterization of human high-grade serous ovarian cancer,” Cell, vol. 166, no. 3, pp. 755–765, 2016.
[24] Y. S. Kim, J. Gum, and I. Brockhausen, “Mucin glycoproteins in neoplasia,” Glycoconjugate Journal, vol. 13, no. 5, pp. 693–707, 1996.
Evidence-Based Complementary and Alternative Medicine

[25] J. H. Yoon, I.-H. Ham, O. Kim et al., “Gastrokine 1 protein is a potential therapeutic target for gastric cancer,” Gastric Cancer, vol. 21, no. 6, pp. 956–967, 2018.

[26] S. Mitra, M. S. Lami, A. Ghosh et al., “Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?” Cancers, vol. 14, no. 3, p. 759, 2022.

[27] M. R. Islam, F. Islam, M. H. Nafady et al., “Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint,” Molecules, vol. 27, no. 7, p. 2165, 2022.

[28] Y. Chao, J. Jin, L. Wang, X. Jin, L. Yang, and B. Zhang, “Transcriptome analysis of IncRNA–mRNA interactions in chronic atrophic gastritis,” Frontiers in Genetics, vol. 11, Article ID 612951, 2020.

[29] S. Y. Park, S. W. Jeon, M. K. Junget al., “Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 10, pp. 966–970, 2008.

[30] Z. Li, T. Yu, X. L. Zuo et al., “Confocal laser endomicroscopy for in vivo diagnosis of gastric intraepithelial neoplasia: a feasibility study,” Gastrointestinal Endoscopy, vol. 72, no. 6, pp. 1146–1153, 2010.

[31] G. N. J. Tytgat, “Endoscopic appearances in gastritis/duodenitis,” Journal of Gastroenterology and Hepatology, vol. 6, no. 3, pp. 223–234, 1991.

[32] C. Iuga, A. Seicean, C. Iancu et al., “Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma,” Proteomics, vol. 14, no. 7-8, pp. 945–955, 2014.

[33] P. Dai, Q. Wang, W. Wang et al., “Unraveling molecular differences of gastric cancer by label-free quantitative proteomics analysis,” International Journal of Molecular Sciences, vol. 17, no. 1, p. 69, 2016.

[34] J. Feng, C. Ding, N. Qiu et al., “Firmiana: towards a one-stop proteomic cloud platform for data processing and analysis,” Nature Biotechnology, vol. 35, no. 5, pp. 409–412, 2017.

[35] C. Zhang, Y. Chen, X. Mao et al., “A Bioinformatic algorithm for analyzing cell signaling using temporal proteomic data,” Proteomics, vol. 17, no. 22, Article ID 1600425, 2017.

[36] P. Sipponen, M. Riihelä, H. Hyvärinen, and K. Seppala, “Chronic nonatrophic (‘superficial’) gastritis increases the risk of gastric carcinoma: a case-control study,” Scandinavian Journal of Gastroenterology, vol. 29, no. 4, pp. 336–340, 1994.

[37] H. Zhang, J. He, Z. Dai et al., “PDDA5 is Correlated with immune infiltration and predicts poor prognosis in gliomas,” Frontiers in Immunology, vol. 12, Article ID 628966, 2021.

[38] Q. Zhang, G. S. Zhao, Y. Cao et al., “Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma,” Oncology Letters, vol. 20, no. 2, pp. 1629–1640, 2020.

[39] M. Watanabe, M. Shibata, T. Inaiishi et al., “MZB1 expression indicates poor prognosis in estrogen receptor-positive breast cancer,” Oncology Letters, vol. 20, no. 5, p. 1, 2020.

[40] H. A. Chawsheen, Q. Ying, H. Jiang, and Q. Wei, “A critical role of the thioredoxin domain containing protein 5 (TXNDC5) in redox homeostasis and cancer development,” Genes & Diseases, vol. 5, no. 4, pp. 312–322, 2018.

[41] C. Zhang, X. Lin, Q. Zhao et al., “YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling,” Journal of Cancer Research and Clinical Oncology, vol. 146, no. 2, pp. 329–342, 2020.

[42] B. Zeng, C. Ge, R. Li et al., “Knockdown of microsomal glutathione S-transferase 1 inhibits lung adenocarcinoma cell proliferation and induces apoptosis,” Biomedicine & Pharmacotherapy, vol. 121, Article ID 109562, 2020.

[43] Y. Kamano, M. Saeki, H. Egusa et al., “PIH1D1 interacts with mTOR complex 1 and enhances ribosome RNA transcription,” FEBS Letters, vol. 587, no. 20, pp. 3303–3308, 2013.

[44] Z. Cui, H. Li, F. Liang et al., “Effect of high WDR5 expression on the hepatocellular carcinoma prognosis,” Oncology Letters, vol. 15, no. 5, pp. 7864–7870, 2018.

[45] Y. Bu, L. Zhang, X. Ma, R. Wang, X. Zhang, and J. Li, “Systematic analysis of the oncogenic role of WDR62 in human tumors,” Disease Markers, vol. 2021, pp. 1–23, 2021.

[46] G. y Sun, J. x Wu, J. s Wu, Yt Pan, and R. Jin, “Caveolin-1, E-cadherin and β-catenin in gastric carcinoma, precancerous tissues and chronic non-atrophic gastritis,” Chinese Journal of Cancer Research, vol. 24, no. 1, pp. 23–28, 2012.

[47] C. Li, Z. Zhang, P. Lv, Y. Zhan, and Q. Zhong, “SCAMP3 promotes glioma proliferation and indicates unfavorable prognosis via multiple pathways,” Oncotargets and Therapy, vol. 13, pp. 3677–3687, 2020.

[48] X. Wu, M. Liu, H. Zhu et al., “Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer,” Journal of Experimental & Clinical Cancer Research, vol. 38, p. 277, 2019.

[49] J. Henri, M.-E. Chagot, M. Bourguet et al., “Deep structural proteomics analysis,” OncoTargets and Therapy, vol. 27, no. 7, pp. 2165, 2022.

[50] X. Wu, M. Liu, H. Zhu et al., “Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer,” Journal of Experimental & Clinical Cancer Research, vol. 38, p. 277, 2019.

[51] J. Huang, D. Xiao, G. Li et al., “EphA2 promotes epithelial–mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells,” Oncogene, vol. 33, no. 21, pp. 2737–2747, 2014.

[52] P. Li, Q. Zhang, and H. Tang, “INPP1 up-regulation by miR-27a contributes to the growth, migration and invasion of human cervical cancer,” Journal of Cellular and Molecular Medicine, vol. 23, no. 11, pp. 7709–7716, 2019.

[53] H. Peng, J. Zheng, Q. Su et al., “VPS53 suppresses malignant properties in colorectal cancer by inducing the autophagy signaling pathway,” Oncotargets and Therapy, vol. 13, pp. 10667–10675, 2020.

[54] J. Huang, D. Xiao, G. Li et al., “EphA2 promotes epithelial–mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells,” Oncogene, vol. 33, no. 21, pp. 2737–2747, 2014.

[55] N. Kočevar, F. Odreman, and A. Vindigni, “Proteomic analysis of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT–PCR,” British Journal of Cancer, vol. 90, no. 3, pp. 665–671, 2004.
[58] I. R. Schlaepfer and M. J. E. Joshi, “CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential,” Endocrinology, vol. 161, no. 2, Article ID bqz046, 2020.

[59] Y. n Wang, Z. l Zeng, J. Lu et al., “CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis,” Oncogene, vol. 37, no. 46, pp. 6025–6040, 2018.

[60] F. A. Leite, R. C. P. Lira, P. F. Fedatto et al., “Low expression of HLA-DRA, HLA-DPA1, and HLA-DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT),” Pediatric Blood and Cancer, vol. 61, no. 11, pp. 1940–1948, 2014.

[61] J. A. Wawrzyniak, A. Bianchi-Smiraglia, W. Bshara et al., “A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion,” Cell Reports, vol. 5, no. 2, pp. 493–507, 2013.